Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

QiC

- PMLiVE

Quality in Care’s 2015 diabetes programme launches at Diabetes UK

Now open for entries to celebrate best practice in NHS diabetes care

- PMLiVE

Boehringer steals lead among NOACs with Pradaxa antidote

Has filed reversal agent for European approval

- PMLiVE

Bayer’s Eylea cleared for wider use in Europe

Macular oedema treatment reached €759m in sales last year

- PMLiVE

UK doctors call on NHS to use Avastin for wet AMD

Controversial practice of using the drug off-label could save the health service £102m

- PMLiVE

Werner Baumann to replace Brandicourt at Bayer

Will assume the role of chairman after the former boss jumped ship to Sanofi

- PMLiVE

Rumour mill intensifies around Bayer’s Brandicourt for Sanofi

Could be named Sanofi chief executive as soon as next March

- PMLiVE

NICE heart attack recommendation for Xarelto

Bayer drug on course for another blood clot indication in England and Wales

- PMLiVE

Xarelto gets new atrial fibrillation label in Europe

First oral anticoagulant to gain EU approval in indication

- PMLiVE

Bayer names head of pharma comms in US

Steven Immergut joins from the US FDA

- PMLiVE

NICE recommends Pradaxa in blood clot indication

Boehringer drug backed to treat and prevent deep vein thrombosis and pulmonary embolism

- PMLiVE

Germany’s IQWiG delivers bad news for Bayer’s Eylea

Says drug provides no additional benefit over Novartis’ rival Lucentis in eye condition

- PMLiVE

ASH: Pradaxa antidote effective in key patient groups

Boehringer posts positive data on use of idarucizumab in elderly and people with kidney impairment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links